Menu
Contact

Press Release Syndication

Icahn Enterprises L.P. Investor Notification: Kessler Topaz Meltzer & Check, LLP Announces July 10, 2023 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Icahn Enterprises L.P.

RADNOR, Pa., June 03, 2023 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against Icahn Enterprises L.P. (“Icahn Enterprises”) (NASDAQ:IEP). The action charges Icahn Enterprises with […]

Read More
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a […]

Read More
FOX, FOXA INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX, FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes […]

Read More
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed an overall response rate of more than 80 percent1,2,3 BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 […]

Read More
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced substantial clinical benefit - - REFRaME-O1, the Phase 2/3 pivotal study of luvelta for […]

Read More
ROSEN, A LEADING LAW FIRM, Encourages Wheels Up Experience Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – UP

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Wheels Up Experience Inc. (NYSE: UP) between November 9, 2022 and March 31, 2023, both dates inclusive (the “Class Period”), of the important June 20, 2023 lead plaintiff deadline in the securities […]

Read More
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Virtu Financial, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VIRT

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Virtu Financial, Inc., (NASDAQ: VIRT) between March 1, 2019 and April 28, 2023, both dates inclusive (the “Class Period”) of the important July 18, 2023 lead plaintiff deadline. SO WHAT: If you […]

Read More
Janssen Presents First Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the Phase 1b RedirecTT-1 study of TECVAYLI®▼ (teclistamab), a BCMAxCD3 bispecific antibody, and talquetamab, a GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma […]

Read More
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages PDD Holdings Inc. f/k/a Pinduoduo Inc. Investors With Losses to Inquire About Securities Class Action Investigation – PDD

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PDD Holdings Inc. f/k/a Pinduoduo Inc. (NASDAQ: PDD) resulting from allegations that PDD may have issued materially misleading business information to the investing public. SO WHAT: If […]

Read More
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

-  Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2nd-line GIST patients; data immature to estimate progression free survival (PFS) -  Combination of bezuclastinib and sunitinib is well-tolerated and consistent with published sunitinib monotherapy safety […]

Read More
1 2 3 4,390
© 2023 BrandPublished.com